AXGN
AxoGen, Inc.
AXGN has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AXGN overall, supported by stronger fundamentals.
AXGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Stable |
AXGN's revenue and cash flow are currently healthy, and its balance sheet is stable, but its profitability is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AXGN PE Valuation
AXGN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AXGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for AXGN, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AXGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.65 | — |
| Q3 2026 | -$0.65 | -$0.59 |
| Q2 2026 | -$0.68 | -$0.57 |
| Q1 2026 | -$0.64 | -$0.48 |
| Q4 2025 | -$0.34 | -$0.11 |
| Q3 2025 | -$0.06 | +$0.25 |
| Q2 2025 | -$0.11 | +$0.26 |
| Q1 2025 | -$0.16 | +$0.33 |
| Q4 2024 | -$0.23 | +$0.28 |
AXGN lost $0.65 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AXGN on earnings quality, reporting a profit while its opponent remains loss making.
AXGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $75.8M | +26% |
| Q2 2026 | $69.7M | +23% |
| Q1 2026 | $61.5M | +27% |
| Q4 2025 | $59.9M | +21% |
| Q3 2025 | $60.1M | +24% |
| Q2 2025 | $56.7M | +18% |
| Q1 2025 | $48.6M | +17% |
| Q4 2024 | $49.4M | +15% |
AXGN's revenue has grown year over year for 18 quarters in a row: $76M last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.3% | -1.9 points |
| Q2 2026 | -3.1% | -6 points |
| Q1 2026 | -4.6% | -1.2 points |
| Q4 2025 | -16% | -20 points |
| Q3 2025 | 3.2% | +3.8 points |
| Q2 2025 | 3% | +3.8 points |
| Q1 2025 | -3.4% | +7.6 points |
| Q4 2024 | 4.1% | +12 points |
AXGN's operating margin was 1.3% last quarter, down 1.9 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AXGN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AXGN on profitability, with a higher operating margin.
AXGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.1M | +789% |
| Q2 2026 | $6.3M | -9.7% |
| Q1 2026 | -$1.2M | +$12.2M |
| Q4 2025 | $1.8M | -78% |
| Q3 2025 | $1.7M | -48% |
| Q2 2025 | $7M | +115% |
| Q1 2025 | -$13.4M | -$245K |
| Q4 2024 | $8.1M | +$9.7M |
AXGN has burned cash in most quarters: $22M over the past year, about seven times what it generated the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AXGN on cash flow, with more consistent year-over-year improvement.
AXGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +8.2M shares |
| 1 year | +25% | +12.4M shares |
| 3 years | +43% | +18.5M shares |
| 5 years | +48% | +20.1M shares |
| Available history | +55% | +21.8M shares |
AXGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2020 | $639,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AXGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 2.3x | Moderate |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 4.7x | High |
| Q4 2024 | 6.3x | High |
AXGN's net debt is about 2.3 years of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AXGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.0 | Neutral |
| Stochastic | 83.0 | Overbought |
AXGN's weekly RSI is 66 (neutral) and its Stochastic is 83 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AXGN PE vs Healthcare Sector
AXGN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AXGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.1 | 29% above |
| 20 week MA | $44.2 | 25% above |
| 50 week MA | $39.2 | 41% above |
| 100 week MA | $27.8 | 100% above |
| 200 week MA | $18.3 | 203% above |
AXGN is in an uptrend: it's above all five of its weekly moving averages, and 203% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
AXGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.6 | $17.7 | -4.8% |
| 2021 | $17.7 | $9.82 | -45% |
| 2022 | $9.82 | $9.94 | +1.2% |
| 2023 | $9.94 | $6.83 | -31% |
| 2024 | $6.83 | $16.7 | +144% |
| 2025 | $16.7 | $32.8 | +97% |
| 2026 YTD | $32.8 | $55.4 | +69% |
AXGN's yearly returns have swung widely, from +144% in 2024 to −45% in 2021. It's up 69% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AXGN on returns for 2026, with the stronger performance.